Since 1984, clinical observations have suggested that Iscador might have a beneficial effect in HIV infection, both as monotherapy and in combination with Retrovir® (AZT). Through collaborative efforts with Professor Maria Linder of the California State University in Fullerton, we received permission from the Food and Drug Administration to conduct a first clinical trial with Iscador® in HIV positives, in healthy non-smoking individuals and in cancer patients (a phase I/II trial).

This study was completed in October of 1994. We were able to document the following:

  1. Iscador® is well-tolerated; no toxicities of any significance were seen.

  2. In most patients (and in several healthy individuals) the quality of life increased remarkably.

  3. The clinical condition of the HIV positives stabilized as well as their T4 helper cell counts. Also, other laboratory tests suggested that the progress of the HIV infection was inhibited.

  4. In a three-dimensional collagen matrix, directly under the microscope, we could document and videotape an increased action against breast cancer cells and colon cancer cells (increased natural killer cell activities) by the white blood cells of the study participants.

At the moment, in Europe, two large international, multi-centered trials in women with cervix dysplasia and in HIV positives will be performed to document the efficacy of Iscador® in these two groups. These studies are in part financially supported by the government of Germany, and by non-profit corporations and foundations.

Source: http://www.healthy.net